...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Financials

The last financials posted by Zenith on Sedar and their website are Jan 2019. I assume since they are not a public company there is no way to access more timely info?

Share
New Message
Please login to post a reply